Rui Henrique Selected Research

Proto-Oncogene Proteins c-ets

7/2013	Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.
2/2013	Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes.
7/2012	Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
3/2012	FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.
1/2012	Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rui Henrique Research Topics

Disease

131	Neoplasms (Cancer) 02/2024 - 10/2003
58	Prostatic Neoplasms (Prostate Cancer) 03/2024 - 11/2004
32	Carcinogenesis 06/2023 - 01/2006
22	Carcinoma (Carcinomatosis) 01/2023 - 05/2002
21	Renal Cell Carcinoma (Grawitz Tumor) 12/2022 - 04/2007
19	Breast Neoplasms (Breast Cancer) 10/2023 - 02/2004
18	Urinary Bladder Neoplasms (Bladder Cancer) 01/2024 - 12/2010
16	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 08/2021 - 02/2005
13	Neoplasm Metastasis (Metastasis) 02/2024 - 01/2017
7	Urologic Neoplasms (Urological Cancer) 09/2023 - 12/2007
7	Colorectal Neoplasms (Colorectal Cancer) 11/2018 - 08/2011
4	Inflammation (Inflammations) 03/2023 - 10/2003
4	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2023 - 12/2019
4	Lung Neoplasms (Lung Cancer) 06/2022 - 12/2013
4	Testicular Germ Cell Tumor 01/2021 - 01/2020
4	Adenocarcinoma 09/2020 - 12/2002
4	Prostatic Intraepithelial Neoplasia 01/2019 - 12/2004
4	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2019 - 08/2015
3	Non-Muscle Invasive Bladder Neoplasms 01/2023 - 01/2020
3	Circulating Neoplastic Cells 12/2022 - 03/2021
3	Abdominal Obesity 10/2022 - 08/2018
3	Kidney Neoplasms (Kidney Cancer) 12/2021 - 01/2011
3	Disease Progression 03/2021 - 10/2019
3	Oxyphilic Adenoma (Oncocytoma) 01/2015 - 07/2007
3	Squamous Cell Carcinoma of Head and Neck 07/2011 - 10/2006
2	Embryonal Carcinoma 02/2024 - 01/2021
2	Fibrosis (Cirrhosis) 03/2023 - 10/2012
2	Residual Neoplasm 01/2023 - 11/2020
2	Esophageal Neoplasms (Esophageal Cancer) 01/2023 - 11/2020
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2022 - 09/2019
2	Fibroadenoma 01/2022 - 05/2008
2	Seminoma 08/2021 - 12/2019
2	Hypoxia (Hypoxemia) 12/2020 - 11/2019
2	Metaplasia 09/2020 - 09/2011
2	Proteinuria 01/2019 - 10/2007
2	Microsatellite Instability 12/2017 - 10/2010

Drug/Important Bio-Agent (IBA)

88	Biomarkers (Surrogate Marker)IBA 03/2024 - 01/2007
32	Proteins (Proteins, Gene)FDA Link 11/2023 - 02/2005
27	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 12/2002
26	MicroRNAs (MicroRNA)IBA 09/2023 - 10/2011
15	Histones (Histone)IBA 01/2024 - 02/2005
13	Messenger RNA (mRNA)IBA 02/2022 - 11/2006
12	EnzymesIBA 12/2021 - 05/2002
11	RNA (Ribonucleic Acid)IBA 01/2024 - 06/2009
11	MethyltransferasesIBA 06/2022 - 05/2011
8	ChromatinIBA 11/2023 - 02/2005
8	Cell-Free Nucleic AcidsIBA 06/2022 - 09/2018
8	Tumor Biomarkers (Tumor Markers)IBA 01/2022 - 01/2007
7	Cisplatin (Platino)FDA LinkGeneric 02/2024 - 01/2017
7	Androgen Receptors (Androgen Receptor)IBA 11/2023 - 10/2011
7	Phenobarbital (Luminal)FDA Link 11/2022 - 04/2016
5	A-Form DNA (A-DNA)IBA 01/2022 - 11/2018
5	Proto-Oncogene Proteins c-etsIBA 07/2013 - 01/2012
4	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 01/2017
4	Cadherins (E-Cadherin)IBA 02/2022 - 09/2005
4	N-methyladenosineIBA 01/2022 - 03/2020
4	Protein Isoforms (Isoforms)IBA 01/2022 - 05/2005
4	6-methyladenineIBA 09/2021 - 12/2019
4	Decitabine FDA Link 01/2020 - 10/2006
4	Histone MethyltransferasesIBA 01/2017 - 01/2015
4	hydrogen sulfite (bisulfite)IBA 05/2014 - 03/2008
3	ProteomeIBA 10/2023 - 01/2021
3	ErbB Receptors (EGF Receptor)IBA 06/2023 - 08/2011
3	Hydralazine (Apresoline)FDA LinkGeneric 08/2021 - 08/2014
3	Prostate-Specific Antigen (Semenogelase)IBA 07/2020 - 10/2007
3	ParaffinIBA 04/2020 - 07/2007
3	NucleosidesIBA 01/2020 - 01/2014
3	Transcription Factors (Transcription Factor)IBA 11/2018 - 01/2011
3	Transforming Growth Factor-beta Type II ReceptorIBA 08/2015 - 10/2010
2	Long Noncoding RNAIBA 01/2024 - 01/2018
2	Hormones (Hormone)IBA 10/2023 - 11/2018
2	AndrogensIBA 10/2023 - 08/2021
2	VaccinesIBA 01/2023 - 12/2019
2	VimentinIBA 01/2023 - 01/2020
2	GuanineIBA 11/2022 - 01/2022
2	CytosineIBA 11/2022 - 01/2022
2	Phosphates (Orthophosphate)IBA 11/2022 - 01/2022
2	PlatinumIBA 06/2022 - 01/2020
2	flavanoneIBA 09/2021 - 01/2021
2	PanobinostatIBA 07/2021 - 10/2020
2	Tamoxifen FDA LinkGeneric 06/2021 - 11/2018
2	Telomerase (Telomerase Reverse Transcriptase)IBA 11/2020 - 06/2019
2	Histone Deacetylase InhibitorsIBA 10/2020 - 05/2011
2	SirtuinsIBA 04/2020 - 01/2020
2	Formaldehyde (Formol)FDA Link 04/2020 - 11/2019
2	Histone Deacetylases (Histone Deacetylase)IBA 01/2020 - 07/2015
2	Sirtuin 1IBA 01/2020 - 10/2013
2	AntibodiesIBA 11/2019 - 09/2011
2	Nonsense Codon (Nonsense Mutation)IBA 01/2019 - 02/2016
2	Volatile Organic CompoundsIBA 01/2018 - 01/2017
2	Calcibiotic Root Canal SealerIBA 12/2017 - 08/2015
2	Histone DemethylasesIBA 01/2017 - 01/2015

Therapy/Procedure

37	Therapeutics 12/2023 - 02/2004
7	Drug Therapy (Chemotherapy) 01/2023 - 09/2010
4	Radiotherapy 12/2020 - 01/2017
3	Neoadjuvant Therapy 05/2023 - 01/2022
3	Immunotherapy 01/2022 - 01/2021
3	Prostatectomy (Retropubic Prostatectomy) 10/2020 - 01/2006
2	Transplantation 10/2023 - 10/2007
2	Secondary Prevention 01/2023 - 01/2023